1. Pink Sheet
  2. >>Geography
  3. >>Europe
  4. >>United Kingdom

England To Get ‘First Ever’ Patient Safety Commissioner Next Year

 
• By Vibha Sharma

The UK government has revealed a number of changes it is making to the health care system in response to a report that found serious lapses regarding the safety of patients who were using certain treatments. 

Image of doctor holding patient's hand to encourage, talking with patient cheering and support.
UK Wants To Improve How Its Health Care System Responds To Patients Concerns • Source: Alamy

England could get its first independent “patient safety commissioner” by early 2022 as part of several new initiatives being rolled out by the government to address the many failings of the UK’s medicines and medical devices safety framework that were highlighted in a scathing report last year.

In its 26 July response to the report, the government said that the new commissioner would have statutory powers...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United Kingdom

England’s NHS Plan Eyes Cancer Vaccine Boost, Single Formulary & ‘Pay For Impact’ Drug Deal

 
• By Eliza Slawther

The creation of a single national formulary for medicines prescribing that could impact industry is among the action points in the UK government’s new 10-year health plan for the National Health Service in England.

UK Pilots Faster Setup Of Early Phase Oncology Trials

 
• By Vibha Sharma

Oncology trial sponsors in the UK are being invited to participate in a pilot that aims to tackle duplication and variation in pharmacy reviews, which are an important part of setting up clinical trials in the National Health Service.

Engage With HTA Body NICE Before Submitting MAA, UK Govt Tells Companies

 
• By Neena Brizmohun

The government has explained how to navigate the UK’s regulatory and market access funding mechanisms.

‘Prices Can Remain Contaminated Indefinitely’: Advanz Brushed Aside On UK Liothyronine Appeal

 
• By Dean Rudge

England’s Court of Appeal has upheld a Competition Appeal Tribunal’s 2023 finding that Advanz and its former owner Cinven abused their dominant position in the UK market for liothyronine tablets by charging prices that were many orders of magnitude higher than the benchmark for fair pricing.

More from Europe